Body fluid retention in chronic dialysis patients is a modifiable risk factor of mortality and cardiovascular events. They often show pulmonary congestion by ultrasonography but remain asymptomatic. Only a few reports have shown that the significant association between Comet score calculated by pulmonary congestion and survival rate. However, there is no data from Japan. We evaluated the Comet score among chronic dialysis patients in Okinawa, Japan and examined the prognosis. METHODS: Multicenter prospective observational study. Comet scores were calculated at the beginning of observation, and divided into 3 groups. Event free survivals (mortality and CVD events) were compared between these groups. RESULTS: We targeted 203 chronic dialysis patients in two facilities. The mean age was 64.7 6 11.5 years, the average dialysis period was 93 6 78 months, the diabetes was 57%, and the average observation period was 24 6 9 months. The average of Comet scores decreased to 8.3 6 11.1 before dialysis and 4.8 6 7.4 after dialysis. There were no difference in Comet score between facilities. There were 10 deaths (5 deaths of infectious diseases) during the observation period and 18 patients for CVD events. There was no association between Comet score and mortality. The event free survival of 24 months of the CVD event was lower in "Comet score 5 or more" than "less than 5" (log rank p <0.05), Unadjusted hazard ratio (HR) 2.52; 95% confidence interval (CI) 1.03 -7.02). The Comet score was related to LAD and LVDd / Ds. CONCLUSIONS: We considered that Comet score in Japan is a predictor of CVD event rather than mortality. It was considered to be a useful and convenient tool for prognostic prediction, even compared with the CTR or IVC evaluation which is normally performed. 
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INTRODUCTION AND AIMS:
Emerging evidence suggests that pulmonary hypertension (PHT), a recently recognized complication of end-stage renal disease (ESRD), is closely associated with cardiac, pulmonary, and systemic diseases and also with increased mortality .The prevalence of PHT is known to range from 18.8% to 68.8% in hemodialysis (HD) patients . The possible causes of PHT in dialysis patients are classified into three categories: (1) increased cardiac output (2) increased pulmonary vascular resistance caused by pulmonary artery calcifications and (3) elevated pulmonary capillary wedge pressure.Although previous results indicated that extra osseous calcifications might be a risk factor for PHT, results in human studies about the association between PHT and pulmonary artery calcification or parathyroid hormone levels have been conflicting .Medial artery calcification is a common complication in patients with chronic kidney disease (CKD) and multiple factors including abnormal calcium phosphate metabolism are known to be important in vascular calcification (VC) development. In this study, we examined the association between PHT and peripheral VCs in dialysis patients.
METHODS:
In this prospective study, we included 60 ESRD patients undergoing dialysis HD for at least 6 months. Baseline characteristics, including sex, age, body weight, height, dialysis duration, causes of ESRD, and history of hypertension, diabetes, ischemic heart disease, and chronic obstructive pulmonary disease were recorded. The mean values of serum albumin, LDL cholesterol, alkaline phosphatase, calcium, phosphate, hemoglobin, and C-reactive protein also have been measured .Standard two-dimensional, M-mode, Doppler echocardiography was performed for all patients. We used the modified Bernoulli equation to calculate pulmonary artery systolic pressure (PASP).The Simple Vascular Calcification Score (SVCS) was measured using plain radiographic films of both hands and pelvis. RESULTS: In this study, we observed the following: (1) HD patients had a high prevalence of PHT (2) Severe peripheral VCs (SVCS >3) were independent risk factors for PHT (3) in addition to the old age, duration of hemodialysis, or severe VCs AND Mitral valve disease , the presence of higher Ca X P product was an independent predictor of PHT in HD patients CONCLUSIONS: The prevalence of PHT in our dialysis patients seems to be high, and PHT is closely associated with peripheral VC, suggesting that the mechanisms underlying the development of CKD-mineral bone disorder might be partially responsible for PHT. Using SVCS scoring system is a simple way to evaluate Peripheral vascular calcification in HD patients.
SP552 RISKS AND BENEFITS OF ORAL ANTICOAGULATION THERAPY IN HEMODIALYSIS PATIENTS
Giuseppe Sileno
INTRODUCTION AND AIMS:
It is still debated whether hemodialysis patients (HD) could benefit from oral anticoagulant therapy (OAT) with vitamin K antagonists (VKA). The aim of this retrospective study was to assess the risk/benefit ratio of using VKA in a population of hemodialysis patients.
METHODS:
We retrospectively enrolled all hemodialysis and chronic kidney disease stage III to V (CKD) patients followed in our Center, from January 1 st , 2010 to June 15 th , 2016, on OAT and a group of age-and sex-matched control patients not on OAT. We divided our cohort into 4 groups: HDþOAT, HD no OAT, CKDþOAT, CKD no OAT. Patients were followed for at least three months. We determined the occurrence of hemorrhagic and ischemic episodes (defined as requiring transfusions or hospitalization) and the mortality incidence. INR was dosed at least every two weeks for hemodialysis patients and according to specialist prescription for outpatients. RESULTS: We enrolled 43, 31, 35 and 31 patients in the HDþOAT, HD no OAT, CKDþOAT and CKD no OAT group respectively. In the HDþOAT group 65% of the patients were on OAT because of non valvular atrial fibrillation, 21% because of previous thromboembolism episodes, 12% because of the presence of mechanical valves and 2% for other reasons while in the CKDþOAT group all patients were on OAT because of AF. The time in therapeutic range (TTR) on the INR for hemodialyzed patients was 38.5613.8%, with an INR<1.5 in 17.1613.5% of the times and an INR>5 in 366.6% of the recorded values. 39.5% of HDþOAT patients presented a hemorrhagic event versus 5% of patients in HD no OAT (p<0.05), 2% in the CKDþOAT group (p<0.001) and 3% in the CKD no OAT group (p<0.001). Incidence of ischemic episodes was 23.3% in HDþOAT vs 9.7% in HD no OAT (p¼NS), 8.6% in CKDþOAT (p¼NS) and 0% in CKD no OAT (p¼0.01). The CHA 2 DS 2 -VASc and Has-BLED scores positively correlated with ischemic (p¼0.004) and hemorrhagic (p¼0.002) events respectively in both HDþOAT and HD no OAT group whereas we couldn't find any correlation for the HAS-BLED score in the CKD groups and the CHA 2 DS 2 -VASc positively correlated with ischemic events in the CKD groups (p¼0.01). Mortality incidence among the different groups was 47% in the HDþOAT group, 3% in the HD no OAT group, 23% in the CKDþOAT group and 0% in the CKD no OAT group. Patients on OAT had a higher mortality both in HD and CKD (p<0,0001 and p<0.01 respectively), and mortality was higher in HD compared to CKD: p<0.05 for patients on OAT and p <0,0001 for patients not on OAT. CONCLUSIONS: Our study shows that keeping the therapeutic range of INR in hemodialysis patients is possible although difficult. Since OAT confers a higher risk of mortality to hemodialysis patients, it should be carefully prescribed in this population weighting the risks and benefits. In this regard, the CHA 2 DS 2 -VASc and HAS-BLED scores proved to be useful in assessing the bleeding and ischemic risk. We generated a mathematical model to predict the BNP level in hemodialysis patients. METHODS: Fifteen clinical and biological variables including BNP were used to generate the model (¼learning dataset). The latter was validated in an independent validation set. RESULTS: The learning dataset included 150 hemodialysis patients (Mean Age 67 years old, BNP 6306717 ng/ml). Cardiac disease (CD¼ Stable Coronary Artery Disease and/ or Atrial Fibrillation) was present in 45%. The Final model includes: Age, systolic Blood Pressure (sBP), Albumin (Alb), the CD, the Normo-hydrated Weight (NHW) assessed by bio-impedancemetry, and the Fluid overload (DeltaW). Age, CD and DeltaW contribute the most to the BNP level, respectively but with some limits. For example, BNP increases only for Age between 30 to 70 years old, before reaching a "ceiling". We observed that BNP level was inversely correlated with NHW. BNP decreases from 360 to 108 ng/ml for a NHW of 45 and 100kg (CD¼0), and from 606 to 317 ng/ml if CD¼1. Finally, our model allows us to anticipate the BNP level according to the FO defined by the DeltaW. For a hemodialysis patient (67 years old man, sBP¼130/80 mmHg), the BNP level increases from 221 to 304 and 418 ng/ml for a DeltaW of 2.5 and 5 kg respectively; and 373 to 514 and 707 ng/ml if CD¼1. 
